L&C Bio Obtains US Patent for Skin ECM-Based Wound Care Technology
Predicted impact: Low
US patent registration for wound-care technology; small, and the patent was already reported.
L&C Bio엘앤씨바이오
290650 · KOSDAQ · ₩290650 · 엘앤씨바이오
₩24,900▼ ₩5,249 (17.41%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −4.89%
- Market cap
- ₩672B
- Enterprise value
- ₩655B
- P/E
- —
- P/B
- 2.1×
- Dividend yield
- 0.2%
- ROE
- −46.0%
- Net margin
- −128.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.4% from the high
₩21,180Today: ₩24,900 – ₩30,000₩62,810
Returns
- 1W−25.8%
- 1M+5.0%
- 3M−14.7%
- 6M−31.6%
- YTD−18.9%
- 1Y−0.4%
- Volume today
- 641,181
- 0.8× the 20-day average
- Traded today
- ₩17B
- Listed shares
- 26,969,704
- EPS (12 months)
- −₩5,540
- Earnings yield −22.2%
AI research · InitiationL&C Bio: Operating Profit Positive but Large Net Loss, With Rights Offering and Bonus Share Filings in FocusThe data shows a business with rising revenue and a recovering operating margin, set against large net losses, negative free cash flow and a pending rights offering whose terms are not given.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−17.4% on Oct 26, 2026.
L&C Bio received a US patent for a wound-care material made from human skin tissue. The news was reported by several Korean outlets on 27 October 2026.
AI summary of the news and filings linked. It can be wrong; check them.
- • Filing: Ex-Rights (Bonus Issue)
- • Foreign investors sold a net ₩4.4B that day
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A new US patent is a positive development for the company. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat8.2% over the last month; the price is below its 20-day average.
- News impactSome15 news items and filings in two weeks; 0 rated high impact, 4 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩1B at the close (3.9% of 20-day average trading value)
On its 32 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 9.1% of trading value and pointed the same way 19 of 32 times.
- 2× KODEX KOSDAQ150 Leverage −₩843M
- -1× KODEX KOSDAQ150 Futures Inverse −₩70M
- 2× TIGER KOSDAQ150 Leverage −₩62M
- 2× RISE KOSDAQ150 Futures Leverage −₩18M
- -1× TIGER KOSDAQ150 Futures Inverse −₩2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.3%
- KODEX KOSDAQ150 Leverage2×0.3%
- TIGER KOSDAQ1500.3%
- RISE KOSDAQ1500.3%
- ACE KOSDAQ 1500.3%
- TIGER KOSDAQ150 Leverage2×0.3%
- KIWOOM KOSDAQ1500.3%
- SOL KOSDAQ1500.3%
Estimated from the funds' index or underlying stock.
L&C Bio stock overview
L&C Bio (엘앤씨바이오, KRX: 290650) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech firm that manufactures and sells human tissue grafts, human tissue-based medical devices, and cosmeceuticals, and also runs a pharmaceutical business, a contract research business for functional cosmetics and health functional foods, and an AI cosmetics recommendation platform. Its shares closed at ₩24,900 on Oct 26, 2026, down 17.41% on the day, giving it a market value of ₩672B.
Key facts
- Market cap
- ₩672B
- Sector
- Biotech & Pharma
- Latest price change
- −17.41%
- As of
- Oct 26, 2026
- Main business
- The company is a Korean biotech firm that manufactures and sells human tissue grafts, human tissue-based medical devices, and cosmeceuticals, and also runs a pharmaceutical business, a contract research business for functional cosmetics and health functional foods, and an AI cosmetics recommendation platform.
Quick answers about L&C Bio
- What does L&C Bio do?
- The company is a Korean biotech firm that manufactures and sells human tissue grafts, human tissue-based medical devices, and cosmeceuticals, and also runs a pharmaceutical business, a contract research business for functional cosmetics and health functional foods, and an AI cosmetics recommendation platform. Its main revenue comes from human tissue grafts and tissue-based medical devices, used in fields such as plastic surgery, burn surgery, and general surgery, including breast reconstruction after breast cancer treatment. It sells directly to major hospitals and clinics in the Seoul metropolitan area, through distributors elsewhere in Korea, and through regional partners and overseas medical conferences abroad, with exports of tissue-based devices to countries such as China and Southeast Asian nations.
- What is the market cap of L&C Bio?
- The market capitalisation of L&C Bio was ₩672B at the close on Oct 26, 2026.
- Who are the largest shareholders of L&C Bio?
- According to the latest official filings, the largest reported holders are Lee Hwan-chul (23.22%, as of Sep 30, 2026); Nau IB 19th Fund (10.50%, as of Aug 12, 2026); Now IB (9.60%, as of Sep 10, 2026).
- When is the next earnings report from L&C Bio?
- Korean companies rarely announce results dates in advance. Based on when L&C Bio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own L&C Bio?
- Yes. The National Pension Service held 1.28% of L&C Bio shares as of Dec 31, 2025.
Company profile
The company is a Korean biotech firm that manufactures and sells human tissue grafts, human tissue-based medical devices, and cosmeceuticals, and also runs a pharmaceutical business, a contract research business for functional cosmetics and health functional foods, and an AI cosmetics recommendation platform. Its main revenue comes from human tissue grafts and tissue-based medical devices, used in fields such as plastic surgery, burn surgery, and general surgery, including breast reconstruction after breast cancer treatment. It sells directly to major hospitals and clinics in the Seoul metropolitan area, through distributors elsewhere in Korea, and through regional partners and overseas medical conferences abroad, with exports of tissue-based devices to countries such as China and Southeast Asian nations.
Written by AI from the company's latest annual report.
- Korean name
- 엘앤씨바이오
- Sector
- Biotech & Pharma
- CEO
- 이환철, 이재호 (각자 대표이사)
- Founded
- Aug 2011
- Listed
- Nov 2018
- Listed shares
- 26,969,704
- Fiscal year ends
- Month 12
- Website
- www.lncbio.co.kr
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
L&C Bio: Patent for wound-treatment material using human skin tissue in the US
Predicted impact: Low
Same US wound-treatment patent news as the other item in this batch.
L&C Bio secures US patent for wound-healing material; expands MegaCure deployment
Predicted impact: Low
US patent for wound-healing material; small relative to ₩671.5B market value, no revenue size given.
Recent filings
See all- Ex-Rights (Bonus Issue)Oct 23, 2026
- Securities Issuance Results (Voluntary Disclosure)Oct 22, 2026
- Securities Issuance Results ReportOct 22, 2026
- Subscription Results of Rights Offering or Stock-Related Bonds, etc. (Voluntary Disclosure)Oct 16, 2026
- Final Determination of Issue Price for Rights OfferingOct 12, 2026
Titles in Korean until English translations are added.
Also known as: L&C Bio / 엘앤씨바이오 / 290650 / KRX:290650
Source: KRX statistical information